Toggle navigation
Home
Our Company
About Us
Our Team
Board of Directors
Xanamem Clinical Advisory Board
Scientific Development Panel
Actinogen Management
ASX Share Price
ASX Announcements
Alzheimer’s Disease
About Alzheimer’s Disease
External Links
Publications
Xanamem
Xanamem
The Cortisol Hypothesis and Alzheimer’s Disease
Mechanism of Action
Actinogen’s Journey to Discorvery
Confirming Xanamem’s Efficacy
Publications
Research & Development
Research & Development
Clinical
Phase I – Single Ascending Dose (SAD)
Phase I – Multiple Ascending Dose (MAD)
Phase II – XanADu
Phase II – About XanADu’s Clinical Endpoints
Phase I – XanaHES
Phase I – Target Occupancy
Pre-Clinical
Target Occupancy
Toxicology
Additional Indications for Xanamem
Cognitive impairment in Mood Disorders & Schizophrenia
Partnership Opportunities
Publications
ACW Investor Centre
ACW Investor Centre
ASX Share Price
ASX Announcements
Investor Contacts
ACW Investor Events
Newsletter and Reports
Frequently Asked Questions
Corporate Governance
Codes and Guidelines
Media Center
Media Center
In The News
Social Media
Media Relations
Industry Events
Gallery
Contact
Contact Us
Location
Company Secretary
Submit
ASX SHARE PRICE
Go to Investor Centre